Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
Humans
Lymphoma, T-Cell, Peripheral
/ diagnosis
Vincristine
/ therapeutic use
Brentuximab Vedotin
Prednisone
Consensus
Follow-Up Studies
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Australia
/ epidemiology
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Biomarkers
AITL
ALCL
PTCL
chemotherapy
peripheral T-cell lymphoma
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
14
09
2021
received:
09
05
2021
accepted:
09
10
2021
pubmed:
21
10
2021
medline:
25
10
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Peripheral T-cell lymphomas (PTCL) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared with aggressive B-cell lymphomas. However, such outcomes are heavily dependent on subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone remain the standard first-line treatment for most aggressive PTCL, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to understand better the pathogenesis of PTCL to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice.
Substances chimiques
Vincristine
5J49Q6B70F
Brentuximab Vedotin
7XL5ISS668
Prednisone
VB0R961HZT
Cyclophosphamide
8N3DW7272P
Doxorubicin
80168379AG
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1806-1817Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. eds. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues, Revised 4th edn. Lyon, France: IARC; 2017.
Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31: 240-6.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-504.
Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012; 30: 3939-46.
Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Path 2014; 38: 768-75.
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014; 124: 1473-80.
Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol 2019; 186: e28-31.
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123: 1293-6.
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171-5.
Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166-70.
Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A et al. IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 2015; 126: 1741-52.
Casulo C, Schoder H, Feeney J, Lim R, Maragulia J, Zelenetz AD et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma 2013; 54: 2163-7.
Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008; 87: 613-21.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-68.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-9.
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24: 2472-9.
Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol 2018; 181: 760-9.
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533-8.
Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee G-W et al. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Int J Haematol 2019; 110: 438-46.
Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418-25.
Fisher R, Gaynor E, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: preliminary results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study. Proc Am Soc Clin Oncol 1992; 315: 1067.
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124: 1570-7.
Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. OncoTargets Ther 2019; 12: 2335-42.
Kim YA, Byun JM, Park K, Bae GH, Lee D, Kim DS et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv 2017; 1: 2138-46.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014; 25: 2211-17.
Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM et al. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leuk Lymphoma 2019; 60: 904-11.
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010; 151: 159-66.
Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 2018; 5: e190-200.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393: 229-40.
Horwitz SM, O'Connor OA, Pro B, Illidge T, Iyer SP, Advani R et al. The Echelon-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+ CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. Blood 2020; 136: 3-5.
Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007; 60: 129-34.
Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011; 22: 1595-600.
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316-23.
Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 2014; 55: 768-72.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 2020; 35: 143-55.
Bachy E, Camus V, Thieblemont C, Casasnovas R-O, Ysebaert L, Damaj GL et al. Final analysis of the Ro-CHOP phase III study (conducted by LYSA): Romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood 2020; 136: 32-3.
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402-8.
Zhang X-M, Li Y-X, Wang W-H, Jin J, Wang S-L, Liu Y-P et al. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified. Int J Radiat Oncol Biol Phys 2012; 85: 1051-6.
Rodríguez-López JL, Patel AK, Balasubramani GK, Glaser SM, Beriwal S, Vargo JA. Treatment selection and survival outcomes in early-stage peripheral T-cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy? Leuk Lymphoma 2021; 62: 538-48.
Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol 2015; 168: 708-18.
Chen Z, Huang H, Li X, Fang X, Wang Z, Hong H et al. Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol 2021; 11: 607145.
d'Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v108-15.
Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92: 11-31.
Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma - not otherwise specified. Crit Rev Oncol Hematol 2011; 79: 321-9.
Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT et al. The optimal use of imaging in radiation therapy for lymphoma: guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2019; 104: 501-12.
Illidge T, Specht L, Yahalom J, Berthelsen AK, Hodgson D, Eich HT et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2014; 89: 49-58.
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86-92.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukaemia 2021; 35: 143-55.
d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Upfront autologuos stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093-9.
Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 2016; 6: e452.
Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019; 125: 1507-17.
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018; 29: 715-23.
Advani R, Skrypets T, Cilallero M, Spinner MA, Manni M, Kim WS et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood 2021; 138: 213-20.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW et al. NCCN guidelines insights: T-cell lymphomas, version 1.2021: featured updates to the NCCN guidelines. J Nat Comp Cancer Netw 2020; 18: 1460-7.
Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017; 23: 1826-38.
Tournilhac O, Truemper L, Ziepert M, Bouabdallah K, Nickelsen M, Maury S et al. First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation - final results of the AATT study. Haematol Oncol 2019; 37: 99-101.
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018; 103: 1191.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130: 2709-17.
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Haematol Oncol 2014; 7: 1-8.
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9: 1567-74.
Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Nat Cancer Inst 2014; 106: 378.
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. Leuk Lymphoma 2017; 58: 2319-27.
Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31: 3100.
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Haematol 2019; 94: 641-9.
Ma H, Cheng B, Falchi L, Acosta M, Federico M, Gisselbrecht C et al. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol 2020; 38: 51-8.
Shustov A, Pro B, Gisselbrecht C, Popplewell L, Bartlett NL, Lechowicz MJ et al. Pralatrexate is effective as second-line treatment following cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Blood 2010; 116: 4882.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182.
Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 2017; 108: 2061-8.
O'Connor OA, Amengual J, Colbourn D, Deng C, Sawas A. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. Leuk Lymphoma 2017; 58: 2548-57.
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leuk Lymphoma 2019; 60: 2927-30.
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014; 123: 3095-100.
Foss F, Pro B, Prince MH, Sokol L, Caballero D, Horwitz S et al. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med 2017; 6: 36-44.
Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G et al. Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS. Hemasphere 2019; 3: e187.
Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood 2018; 132: 2305-9.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018; 131: 397-407.
O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019; 134: 1395-405.
Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007; 48: 521-5.
Kim W, Song S-Y, Ahn Y, Baek CH, Kim D et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-52.
Qi S-N, Yang Y, Song Y-Q, Wang Y, He X, Hu C et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv 2020; 4: 3141-53.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012; 30: 4044-6.
Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W et al. Phase 2 trial of “sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer 2012; 118: 3294-301.
Kwong Y-L, Kim WS, Lim ST, Yang Q, Xie L, Liu W et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973-80.
Kwong Y, Kim S, Tse E, Oh S, Kwak J, Eom H et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol 2018; 29: 256-63.
Wang X, Zhang L, Liu X, Li X, Li L, Fu X et al. Efficacy and survival in newly diagnosed advanced extranodal natural killer/T-cell lymphoma: a randomized, controlled, multicenter and open-labled study with Ddgp regimen versus SMILE regimen. Blood 2019; 134: 463.
Ghione P, Qi S, Imber BS, Seshan V, Moskowitz A, Galasso N et al. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. Leuk Lymphoma 2020; 61: 3331-41.
Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Brit J Haematol 2018; 182: 916-20.
Zhou Z, Li X, Chen C, Al Malki M, Jacobsen E, Steinberg A et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Haematol 2014; 93: 1889-94.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117: 1834-9.
Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Haematol Oncol 2018; 11: 1-8.
Kwong Y-L, Chan TS, Tan D, Kim SJ, Poon LM, Mow B et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 2017; 129: 2437-42.
Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010; 115: 3664-70.
Wöhrer S, Chott A, Drach J, Püspök A, Hejna M, Hoffmann M et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol 2004; 15: 1680-3.
Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995; 21: 123-9.
Novakonic BJ, Novakonic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep 2006; 16: 191-5.
Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18: 795-5.
Wu H-B, Wang Q-S, Wang M-F, Lim R, Maragulia J, Zelenetz AD et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nuc Med Comm 2010; 31: 195-200.
Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis. Medicine (Baltimore) 2014; 93: e258.